Bronconex Acticap

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Mometasone furoate 400ug (anhydrous)

Disponible depuis:

Organon (New Zealand) Limited

DCI (Dénomination commune internationale):

Mometasone furoate 400 µg (anhydrous)

Dosage:

400 mcg/dose

forme pharmaceutique:

Powder for inhalation

Composition:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Unités en paquet:

Inhaler, metered, DPI, (sample), 14 dose units

classe:

Prescription

Type d'ordonnance:

Prescription

Fabriqué par:

MSD International GmbH (Singapore Branch)

indications thérapeutiques:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Descriptif du produit:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Date de l'autorisation:

2000-12-05